IPPRA / Grant Monitor

2026-07-07
← Board

Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)

PAR-25-327 · National Institutes of Health

biomedical clinical public health computing communications ai data science Health

Closes
2027-10-08 · 458 d
Award ceiling
Award floor
Program funding
Expected awards
Cost sharing
No
Posted
2024-12-18
Instrument
Cooperative Agreement
Characterization · gpt-5.4-mini · 2026-07-07

NIH cooperative agreements fund IND-enabling studies and planning for first-in-human gene-based or transcript-directed therapies aimed at ultra-rare neurological or neuromuscular disorders.

Funds
applied research
University
direct
physical sciences
minor
engineering
minor
life biomedical
central
computational data
minor

⚑ Clinical Trial Optional · Supports IND-enabling studies and planning toward first-in-human clinical testing; cooperative agreement mechanism · Foreign organizations are listed as eligible, but non-domestic components of U.S. organizations are not eligible · No award ceiling provided in notice

Unit fits — one characterization, each unit's own rules

Physical Sciences & Engineering (demo) 65 good technical depth: minor; funds applied research
IPPRA 45 partial peripheral portfolio topic: public_health; social/behavioral work is none; funds applied research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); clinical-trial/biomedical core — IPPRA angle is policy/community (capped); capped at 45 (limited social-science role)
Tom Love Innovation Hub 45 partial funds applied research; prototyping/demonstration stage; deep-tech content

Description

The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this announcement is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Apply

View on Grants.gov → CONTACT: National Institutes of Health <grantsinfo@nih.gov>

Proposal brief SEE AN EXAMPLE →

A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.

ONE LLM CALL (~1¢) · CACHED · REQUIRES STAFF KEY

Proposal shell · National Institutes of Health conventions SEE AN NIH EXAMPLE →

Funder-faithful document skeletons — National Institutes of Health's document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.

ONE LLM CALL (~2-3¢) · CACHED · SCAFFOLDING, NOT GHOSTWRITING